Contents

Search

lymphocyte function-associated antigen 1 (LFA-1) antagonist

Mechanism of action: - inhibits LFA-1

Related

lymphocyte function-associated antigen-1 (LFA-1, leukocyte adhesion protein LFA-1, integrin alpha-L/beta-2, CD11a/CD18)

Specific

lifitegrast (Xiidra)

General

receptor antagonist

References

  1. FDA News Release. July 12, 2016 FDA approves new medication for dry eye disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm510720.htm